A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Zanubrutinib (BGB-3111) in Subjects With Varying Degrees of Hepatic Impairment

Trial Profile

A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Zanubrutinib (BGB-3111) in Subjects With Varying Degrees of Hepatic Impairment

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Liver failure; Lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Sponsors BeiGene
  • Most Recent Events

    • 07 Jun 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 25 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
    • 17 Apr 2018 Planned initiation date changed from 21 Mar 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top